H.C. Wainwright lowered the firm’s price target on Biohaven to $59 from $63 and keeps a Buy rating on the shares post the Q1 report. The analyst cites share dilution for the target cut. Biohaven plans to accelerate the development of BHV-1300 across additional autoantibody-mediated targets, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN: